Jacobs Levy Equity Management Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Jacobs Levy Equity Management Inc. decreased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 49.6% in the 4th quarter, HoldingsChannel reports. The firm owned 742,462 shares of the biopharmaceutical company’s stock after selling 729,255 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Sangamo Therapeutics were worth $757,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. E Fund Management Co. Ltd. purchased a new position in Sangamo Therapeutics in the fourth quarter worth approximately $25,000. JPMorgan Chase & Co. lifted its stake in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in Sangamo Therapeutics in the fourth quarter worth approximately $28,000. Finally, Shelton Wealth Management LLC purchased a new position in Sangamo Therapeutics in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SGMO. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Truist Financial cut their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Finally, Barclays cut their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $4.50.

Sangamo Therapeutics Trading Up 4.4%

SGMO stock opened at $0.47 on Friday. Sangamo Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $3.18. The company’s 50 day moving average is $0.73 and its two-hundred day moving average is $1.32. The stock has a market cap of $107.72 million, a P/E ratio of -0.63 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, equities research analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.